NUMA1 and urinary bladder carcinoma: MCM5 combined with other urinary markers, such as NMP22 and UroVysion, can significantly enhance its clinical usefulness and result in a less expensive and more sensitive bladder cancer diagnosis and monitoring procedure [69].